Angel Biotechnology, the AIM listed producer of proteins and cell therapies, has signed a further three manufacturing contracts with Materia Medica worth in excess of £4.5m.
The agreement, which has seen Angel's stock rocket 13.7% this morning, is expected to take 22 months to complete.
Initial production will take place in Edinburgh but the company hopes to transfer activities to its recommissioned site in Cramlington, near Newcastle, during 2012.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Materia and Angel had already agreed to form a joint venture in October last year and the contracts for this work will transfer to the joint entity.
Dr Paul Harper, the Executive Chairman of Angel Biotechnology said the deal put the joint venture on to a "sure footing" while Professor Oleg Epstein from Materia said he believed the deal will enable the firms to bring new products to market in a "timely manner".
Over the last 12 months Angel has lost 35% of its value.
BS
-
Bitcoin price one of the most-asked questions on Alexa - here's how to buy the cryptocurrencyAccording to figures from Amazon, which cover September 2023 to November 2024, pop star Taylor Swift and Bitcoin were named among the most popular Alexa queries of 2024
-
Investing for children this Christmas – five ideasIt might not come with a shiny ribbon, but an investment fund could be the gift that keeps on giving. We share five ideas if you are investing for children this Christmas.
